Beacon is the No. 1 oncology company of Bangladesh & manufactures latest anticancer drugs……..
Crizonix is the global first generic preparation of Crizotinib
Crizonix is indicated as the first-line treatment of adults with ALK-positive advanced Non-Small Cell Lung Cancer(NSCLC) and ROS-1 positive NSCLC. Crizotinib is an ALK and ROS-1 (c-ros oncogene 1 receptor tyrosine kinase) inhibitor.
Special features of Crizonix-
- Manufactured in a dedicated oncology facility
- Quality of Crizonix is to that of International Standard GMP compliant
- Affordable to al patients at 13 times lesser price than originator
- Worldwide delivery to your door step.
Click here to learn more
BEACON Pharmaceuticals Limited launched US FDA approved Crizotinib at an affordable price for patients with NSCLC-
- whose tumors are anaplastic lymphoma kinase (ALK) positive (see clinical studies) &
- whose tumors are ROS-1 positive
It is in capsule form & has to take twice daily.
Crizotinib is the only US FDA approved treatment for patients with ALK positive & ROS-1 positive NSCLC. It is not yet known whether Crizonix is safe and effective in children.
Serving Breakthrough
Therapy
Know About Lung
Cancer
Latest News
& Media
Beacon Introduces Global Patient Support Program
Life saving drugs are either beyond the reach of general
people or not available in many countries. Because of
the patient exemptions for Bangladeshi companies,
Beacon Pharmaceuticals can manufacture the patented
drugs. As a support to global patient… Read more
Registered & Licensed by Regulatory
Authority of Bangladesh
Crizonix is a registered product by the Directorate General
of Drug Administration & Licensing Authority (Drugs) of
Bangladesh. Drug Registration Number: 341-293-10
Inclusion Date: 20-07-2016 Valid up to: 19-07-2021